8 million patient records reveal Real-World COVID-19 treatment insights
NCT ID NCT06085924
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 22 times
Summary
This study used health records from over 8 million COVID-19 patients in Taiwan to understand the disease's impact and how well the oral antiviral nirmatrelvir/ritonavir works in real-world settings. Researchers compared patients who did and did not receive the treatment to see who needed hospital care or had severe outcomes. The goal was to better identify high-risk patients and improve treatment strategies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Taiwan
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.